<?xml version='1.0' encoding='utf-8'?>
<document id="28197979"><sentence text="No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers."><entity charOffset="13-37" id="DDI-PubMed.28197979.s1.e0" text="Omega-3 Carboxylic Acids" /><entity charOffset="78-86" id="DDI-PubMed.28197979.s1.e1" text="Warfarin" /><entity charOffset="137-157" id="DDI-PubMed.28197979.s1.e2" text="Acetylsalicylic Acid" /><pair ddi="false" e1="DDI-PubMed.28197979.s1.e0" e2="DDI-PubMed.28197979.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28197979.s1.e0" e2="DDI-PubMed.28197979.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s1.e0" e2="DDI-PubMed.28197979.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s1.e1" e2="DDI-PubMed.28197979.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s1.e1" e2="DDI-PubMed.28197979.s1.e2" /></sentence><sentence text="Omega-3 carboxylic acids (OM3-CA) can lower triglyceride levels"><entity charOffset="0-24" id="DDI-PubMed.28197979.s2.e0" text="Omega-3 carboxylic acids" /><entity charOffset="26-32" id="DDI-PubMed.28197979.s2.e1" text="OM3-CA" /><entity charOffset="44-56" id="DDI-PubMed.28197979.s2.e2" text="triglyceride" /><pair ddi="false" e1="DDI-PubMed.28197979.s2.e0" e2="DDI-PubMed.28197979.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28197979.s2.e0" e2="DDI-PubMed.28197979.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s2.e0" e2="DDI-PubMed.28197979.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s2.e1" e2="DDI-PubMed.28197979.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s2.e1" e2="DDI-PubMed.28197979.s2.e2" /></sentence><sentence text="" /><sentence text="Our objective was to assess the effects of OM3-CA on warfarin pharmacokinetics and pharmacodynamics and on acetylsalicylic acid (ASA)-dependent and independent platelet activation when co-administered with ASA in two phase I studies"><entity charOffset="43-49" id="DDI-PubMed.28197979.s4.e0" text="OM3-CA" /><entity charOffset="107-127" id="DDI-PubMed.28197979.s4.e1" text="acetylsalicylic acid" /><entity charOffset="206-209" id="DDI-PubMed.28197979.s4.e2" text="ASA" /><entity charOffset="129-131" id="DDI-PubMed.28197979.s4.e3" text="ASA" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e0" e2="DDI-PubMed.28197979.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e0" e2="DDI-PubMed.28197979.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e0" e2="DDI-PubMed.28197979.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e0" e2="DDI-PubMed.28197979.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e1" e2="DDI-PubMed.28197979.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e1" e2="DDI-PubMed.28197979.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e1" e2="DDI-PubMed.28197979.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e3" e2="DDI-PubMed.28197979.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28197979.s4.e3" e2="DDI-PubMed.28197979.s4.e2" /></sentence><sentence text="" /><sentence text="In ECLIPSE II (NCT01431690), 26 participants received warfarin 25 mg on days 1 and 22 and OM3-CA 4 g once daily from day 8 to day 28" /><sentence text=" In OM-EPA-007 (NCT01486433), 52 participants received simvastatin 40 mg plus ASA 81 mg once daily for 14 days, with or without OM3-CA 4 g"><entity charOffset="4-14" id="DDI-PubMed.28197979.s7.e0" text="OM-EPA-007" /><entity charOffset="55-66" id="DDI-PubMed.28197979.s7.e1" text="simvastatin" /><entity charOffset="78-88" id="DDI-PubMed.28197979.s7.e2" text="ASA" /><pair ddi="false" e1="DDI-PubMed.28197979.s7.e0" e2="DDI-PubMed.28197979.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28197979.s7.e0" e2="DDI-PubMed.28197979.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s7.e0" e2="DDI-PubMed.28197979.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s7.e1" e2="DDI-PubMed.28197979.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s7.e1" e2="DDI-PubMed.28197979.s7.e2" /></sentence><sentence text=" Lack of a drug-drug interaction was indicated when 90% confidence intervals (CIs) fell entirely within the range 80-125% for least-squares mean (LSM) ratios of area under the concentration-time curve (AUC), maximum observed plasma concentration (C max), international normalized ratio (INR) AUC to 168 h and maximum INR" /><sentence text="" /><sentence text="In ECLIPSE II, 90% CIs for LSM ratios of with:without OM3-CA fell within 80-125% for AUC and C max of S- and R-warfarin enantiomers" /><sentence text=" The 90% CIs for LSM ratios of with:without OM3-CA fell within 80-125% for INR AUC to 168 h after dosing and for maximum INR of warfarin" /><sentence text=" In OM-EPA-007, no significant effect of OM3-CA was observed on ASA-dependent or ASA-independent platelet activation"><entity charOffset="4-14" id="DDI-PubMed.28197979.s12.e0" text="OM-EPA-007" /><entity charOffset="41-47" id="DDI-PubMed.28197979.s12.e1" text="OM3-CA" /><entity charOffset="64-69" id="DDI-PubMed.28197979.s12.e2" text="ASA" /><entity charOffset="81-86" id="DDI-PubMed.28197979.s12.e3" text="ASA" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e0" e2="DDI-PubMed.28197979.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e0" e2="DDI-PubMed.28197979.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e0" e2="DDI-PubMed.28197979.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e0" e2="DDI-PubMed.28197979.s12.e3" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e1" e2="DDI-PubMed.28197979.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e1" e2="DDI-PubMed.28197979.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e1" e2="DDI-PubMed.28197979.s12.e3" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e2" e2="DDI-PubMed.28197979.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28197979.s12.e2" e2="DDI-PubMed.28197979.s12.e3" /></sentence><sentence text=" No deaths or serious adverse events occurred in either study" /><sentence text="" /><sentence text="OM3-CA did not affect the pharmacokinetics or pharmacodynamics of warfarin or the pharmacodynamic effects of ASA"><entity charOffset="109-111" id="DDI-PubMed.28197979.s15.e0" text="ASA" /></sentence><sentence text=" OM3-CA did not affect platelet function when co-administered with ASA"><entity charOffset="67-69" id="DDI-PubMed.28197979.s16.e0" text="ASA" /></sentence><sentence text="" /></document>